RxDoctor Payments Data

Naba Sharif

Allergy & Immunology · Princeton, NJNPI 1164640892

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,736 of the $8,536 with a category attached, or 78.9%. 33 manufacturers reported payments, led by Sanofi at 26.7% of the total. 2025 is the largest year on record at $3,066, 4.3 times the $715 reported in 2019.

$8,536in general payments, 2019–2025

Across 348 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • AstraZeneca$2K
  • Regeneron Healthcare Solutions, Inc.$678
  • GSK$650
  • CSL Behring$337
  • Optinose US, Inc.$318
  • plus $2K from 27 others

What the payments were for

  • Consulting fees$1,47917%
  • Food & beverage$6,73679%
  • Education$3214%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,536 in reported general payments places this provider in the 65th percentile of 135 allergy & immunology providers in New Jersey.

See all allergy & immunology providers in New Jersey

Medicare billing

Part B allowed, 2024
$38,817
Medicare patients
121
Services billed
3,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol11$6,579
Epinephrine13$2,070
Azelastine Hcl50$1,073
Fluticasone Propionate52$714
Ipratropium Bromide23$423
Albuterol Sulfate HfaAlbuterol Sulfate15$330
Montelukast Sodium13$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$650$6,57911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 135 allergy & immunology providers in New Jersey.

Other allergy & immunology in Princeton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →